Ligand Pharmaceuticals Incorporated

LGND • NASDAQ

$281.72+$1.54 (0.55%)

Estimate

P/E

28.8

EPS

9.78

Beta

0.983

Growth

Revenue, YoY

33.73%

Net income, YoY

900.78%

FCF, YoY

53.96%

Forecast

P/E (FWD)

23.5

EPS (FWD)

11.967

About the company

Ticker

LGND

ISIN

US53220K5048

Country

United States of America

Sector (GICS)

Healthcare

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Frequently asked questions

What sector does Ligand Pharmaceuticals Incorporated (LGND) operate in?

Ligand Pharmaceuticals Incorporated belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Ligand Pharmaceuticals Incorporated (LGND) current stock price?

As of the latest data, Ligand Pharmaceuticals Incorporated stock price is $281.72, with a previous close of $280.18. Ligand Pharmaceuticals Incorporated gained $1.54 in the last trading session, representing a 0.55% increase.

What is Ligand Pharmaceuticals Incorporated (LGND) current market capitalization?

Ligand Pharmaceuticals Incorporated market cap is approximately 5.62 billion.

What is Ligand Pharmaceuticals Incorporated (LGND) Earnings Per Share (EPS)?

The trailing EPS is $9.78, and the forward EPS is $11.97.

What is Ligand Pharmaceuticals Incorporated (LGND) Price-to-Earnings (P/E) ratio?

Ligand Pharmaceuticals Incorporated current P/E ratio is 28.81, with a forward P/E of 23.54.

What is Ligand Pharmaceuticals Incorporated (LGND) EBITDA?

Ligand Pharmaceuticals Incorporated EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 72.40 million.

Does Ligand Pharmaceuticals Incorporated (LGND) pay dividends?

No. Ligand Pharmaceuticals Incorporated does not pay a dividend.

How did Ligand Pharmaceuticals Incorporated (LGND) perform in its most recent earnings report?

In the last report (June 30, 2026), Ligand Pharmaceuticals Incorporated posted an EPS surprise of 65.67% and a revenue surprise of 3.96%.

What is Ligand Pharmaceuticals Incorporated (LGND) beta (volatility) score?

Ligand Pharmaceuticals Incorporated has a beta of 0.983, meaning its volatility is roughly in line with the market.